Cite
Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design.
MLA
Trachtman, Howard, et al. “Novel Therapies for Resistant Focal Segmental Glomerulosclerosis (FONT) Phase II Clinical Trial: Study Design.” BMC Nephrology, vol. 12, Feb. 2011, p. 8. EBSCOhost, https://doi.org/10.1186/1471-2369-12-8.
APA
Trachtman, H., Vento, S., Gipson, D., Wickman, L., Gassman, J., Joy, M., Savin, V., Somers, M., Pinsk, M., & Greene, T. (2011). Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design. BMC Nephrology, 12, 8. https://doi.org/10.1186/1471-2369-12-8
Chicago
Trachtman, Howard, Suzanne Vento, Debbie Gipson, Larysa Wickman, Jennifer Gassman, Melanie Joy, Virginia Savin, Michael Somers, Maury Pinsk, and Tom Greene. 2011. “Novel Therapies for Resistant Focal Segmental Glomerulosclerosis (FONT) Phase II Clinical Trial: Study Design.” BMC Nephrology 12 (February): 8. doi:10.1186/1471-2369-12-8.